Clinical trial · no report yet · Phase 3
KRYSTAL-10
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
- NCT04793958 ↗
- Active, not recruiting
- Mirati Therapeutics Inc.
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 15 | |
| YouTube | 13 | |
| Podcasts | 13 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Advanced Colorectal Cancer; Metastatic Colorectal Cancer
- Interventions
- MRTX849; Cetuximab; mFOLFOX6 Regimen; FOLFIRI Regimen
- Arms
- MRTX849 + Cetuximab · Experimental
- mFOLFOX6 or FOLFIRI · Active comparator
- Enrollment
- 461
- Primary outcomes
- Overall Survival (OS)
- Progression-free Survival (PFS)
- Sponsor
- Mirati Therapeutics Inc.
- Start
- Jun 24, 2021
- Primary completion
- Jan 16, 2026
- Results posted
- No
- Registry record
- NCT04793958 · updated Sep 28, 2026
Publications
linked from the registry- Deming DA. Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2025 Jan 3;23(1):e247067. doi: 10.6004/jnccn.2024.7067. PubMed 39752885